Trial Profile
A Phase II, Open-label, Partially Randomized, 3 Treatment Groups, Multi-Site Study Assessing Pharmacokinetics After Administration of the Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) at Different Injection Sites in Opioid-Dependent Subjects With Chronic Pain
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders; Pain
- Focus Pharmacokinetics
- Sponsors Braeburn Pharmaceuticals
- 16 Aug 2023 Results published in the Clinical Pharmacokinetics
- 29 Apr 2020 Status changed from active, no longer recruiting to completed.
- 12 Jul 2017 Topline results published in the Braeburn Pharmaceutical media Release.